Today could be a major turning point for the UK biotech sector, as changes in government policy could help channel billions of new investment into drug discovery and development.
Simon Stevens hails success in negotiating with pharma companies on price and data, and has defended NHS England’s record in promoting innovative medicines.
The UK pharma industry association yesterday declared war on the latest NHS price control system – but the UK biotech industry counterpart seems far from convinced the move is helpful.
